Rocket Pharmaceuticals
RCKT
Performance
About Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biopharmaceutical company focused on developing gene and molecular therapies to treat rare genetic diseases, with a particular emphasis on cardiac and other organ-specific conditions. The company conducts research and clinical trials globally, including programs for Danon disease and other rare cardiovascular disorders, with corporate and R&D headquarters in Cranbury, New Jersey and presence in New York. Their work aims to move gene therapies from research to approved treatments that address root causes of disease and improve patient outcomes. They also emphasize patient resources and collaboration with healthcare professionals and regulatory bodies to advance rare-disease therapeutics.
Recent News
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
FDA Grants First Gene‑Therapy Approval for Rare Pediatric Immune Disorder LAD‑I
Weekly Reads: 1st FDA-Approved CIRM Supported Therapy, Asymmetric Histone Inheritance, Stem Cell Retraction
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
JPM Day 3: Rare Disease in the Spotlight
Recent Deals
No recent deals for this company.
